Bonnie W Ramsey

List of Publications by Year
in descending order

39 papers	12,726 citations	331670 21 h-index	315739 38 g-index
39 all docs	39 docs citations	39 times ranked	7047 citing authors

#	Article	IF	Citations
1	Impact of guideline-recommended dietitian assessments on weight gain in infants with cystic fibrosis. Journal of Cystic Fibrosis, 2022, 21, 115-122.	0.7	6
2	Cystic Fibrosis: A Disease in Transformation, yet More Work to Be Done!. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 487-489.	5.6	2
3	Impact of azithromycin on serum inflammatory markers in children with cystic fibrosis and new Pseudomonas. Journal of Cystic Fibrosis, 2022, 21, 946-949.	0.7	5
4	A new path for CF clinical trials through the use of historical controls. Journal of Cystic Fibrosis, 2022, 21, 293-299.	0.7	3
5	Long-term azithromycin use is not associated with QT prolongation in children with cystic fibrosis. Journal of Cystic Fibrosis, 2021, 20, e16-e18.	0.7	6
6	Gastrointestinal Factors Associated With Hospitalization in Infants With Cystic Fibrosis: Results From the Baby Observational and Nutrition Study. Journal of Pediatric Gastroenterology and Nutrition, 2021, 73, 395-402.	1.8	7
7	A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 1522-1532.	5.6	146
8	Triple Therapy for Cystic Fibrosis Phe508delâ€“Gating and â€“Residual Function Genotypes. New England Journal of Medicine, 2021, 385, 815-825.	27.0	140
9	Transparency and diversity in cystic fibrosis research â€“ Authors' reply. Lancet, The, 2020, 396, 602.	13.7	0
10	Caring for gender diverse youth with cystic fibrosis. Journal of Cystic Fibrosis, 2020, 19, 1018-1020.	0.7	5
11	Elexacaftorâ€“Tezacaftorâ€“Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. New England Journal of Medicine, 2019, 381, 1809-1819.	27.0	1,231
12	Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet, The, 2019, 394, 1940-1948.	13.7	804
13	Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two F508del alleles. ERJ Open Research, 2019, 5, 00082-2019.	2.6	72
14	Update in Cystic Fibrosis 2018. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 1188-1194.	5.6	13
15	Pancreatic Enzyme Replacement Therapy Use in Infants With Cystic Fibrosis Diagnosed by Newborn Screening. Journal of Pediatric Gastroenterology and Nutrition, 2018, 66, 657-663.	1.8	21
16	AJRCCM: 100-Y<scp>ear</scp> A<scp>nniversary</scp>.Progress along the Pathway of Discovery Leading to Treatment and Cure of Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 1092-1099.	5.6	25
17	Academic, Foundation, and Industry Collaboration in Finding New Therapies. New England Journal of Medicine, 2017, 376, 1762-1769.	27.0	57
18	Home Monitoring of Patients with Cystic Fibrosis to Identify and Treat Acute Pulmonary Exacerbations. eICE Study Results. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 1144-1151.	5.6	96

#	Article	IF	Citations
19	Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis. Lancet Respiratory Medicine,the, 2016, 4, 617-626.	10.7	129
20	Continuous alternating inhaled antibiotics for chronic pseudomonal infection in cystic fibrosis. Journal of Cystic Fibrosis, 2016, 15, 809-815.	0.7	50
21	Breakthrough therapies: Cystic fibrosis (CF) potentiators and correctors. Pediatric Pulmonology, 2015, 50, S3-S13.	2.0	56
22	Lumacaftorâ€“Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508delCFTR. New England Journal of Medicine, 2015, 373, 220-231.	27.0	1,308
23	Standardization of Researchâ€Quality Anthropometric Measurement of Infants and Implementation in a Multicenter Study. Clinical and Translational Science, 2015, 8, 330-333.	3.1	9
24	Pseudomonas aeruginosa in Cystic Fibrosis Patients With G551D-CFTR Treated With Ivacaftor. Clinical Infectious Diseases, 2015, 60, 703-712.	5.8	198
25	Clinical Mechanism of the Cystic Fibrosis Transmembrane Conductance Regulator Potentiator Ivacaftor in G551D-mediated Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 175-184.	5.6	447
26	Serology as a diagnostic tool for predicting initialPseudomonas aeruginosa acquisition in childrenwith cystic fibrosis. Journal of Cystic Fibrosis, 2014, 13, 542-549.	0.7	15
27	Early attained weight and length predict growth faltering better than velocity measures in infants with CF. Journal of Cystic Fibrosis, 2014, 13, 723-729.	0.7	12
28	Future Directions in Early Cystic Fibrosis Lung Disease Research. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 887-892.	5.6	68
29	A CFTR Potentiator in Patients with Cystic Fibrosis and theG551DMutation. New England Journal of Medicine, 2011, 365, 1663-1672.	27.0	1,920
30	Effect of VX-770 in Persons with Cystic Fibrosis and the G551D-CFTRMutation. New England Journal of Medicine, 2010, 363, 1991-2003.	27.0	741
31	The Cystic Fibrosis Foundation Therapeutics Development Network: A National Effort by the Cystic Fibrosis Foundation to Build a Clinical Trials Network. Children's Health Care, 2008, 37, 5-20.	0.9	4
32	Use of Lung Imaging Studies as Outcome Measures for Development of New Therapies in Cystic Fibrosis. Proceedings of the American Thoracic Society, 2007, 4, 359-363.	3.5	9
33	Appropriate compensation of pediatric research participants: Thoughts from an Institute of Medicine committee report. Journal of Pediatrics, 2006, 149, S15-S19.	1.8	11
34	Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2003, 168, 918-951.	5.6	1,451
35	Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis*. Pediatric Pulmonology, 2001, 32, 356-366.	2.0	361
36	Intermittent Administration of Inhaled Tobramycin in Patients with Cystic Fibrosis. New England Journal of Medicine, 1999, 340, 23-30.	27.0	1,226

#	Article	IF	Citations
37	Effect of Aerosolized Recombinant Human DNase on Exacerbations of Respiratory Symptoms and on Pulmonary Function in Patients with Cystic Fibrosis. New England Journal of Medicine, 1994, 331, 637-642.	27.0	1,929
38	Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis. Pediatric Pulmonology, 1989, 7, 265-271.	2.0	142
39	Comparative Monovalent Cation Transport in Neonatal and Adult Red Blood Cells. Pediatric Research, 1984, 18, 778-780.	2.3	1